The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 28, 2016

Filed:

Dec. 11, 2014
Applicants:

Imclone Llc, Indianapolis, IN (US);

Immunogen, Inc., Waltham, MA (US);

Inventors:

Paul J. Balderes, New York, NY (US);

Scott W. Eastman, New York, NY (US);

Hans K. Erickson, Waltham, MA (US);

Dale L. Ludwig, Denville, NJ (US);

Christopher M. Moxham, Princeton Junction, NJ (US);

Gregory D. Plowman, New York, NY (US);

Alan C. Rigby, Glen Ridge, NJ (US);

Assignees:

ImClone, LLC, Indianapolis, IN (US);

ImmunoGen, Inc., Waltham, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 47/48 (2006.01); A61K 45/06 (2006.01); A61K 31/395 (2006.01); A61K 31/559 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
A61K 47/48561 (2013.01); A61K 31/395 (2013.01); A61K 31/559 (2013.01); A61K 45/06 (2013.01); A61K 47/4863 (2013.01); A61K 47/48384 (2013.01); A61K 47/48569 (2013.01); A61K 47/48607 (2013.01); A61K 47/48715 (2013.01); G01N 33/57484 (2013.01); G01N 2333/50 (2013.01); G01N 2800/52 (2013.01);
Abstract

The invention provides conjugates that consist of a drug moiety agent and a cell binding agent that target human fibroblast growth factor receptor 3 (FGFR3). These conjugates have therapeutic use as they are designed and tailored to target a specific cell population and deliver a powerful cytotoxin inside the cell. The conjugate of the present invention has significant advantages over other conjugates known in the art by providing a targeted tumor therapy as well as bystander activity to neighboring cells in an important oncology receptor that is only moderately expressed.


Find Patent Forward Citations

Loading…